Glynn M, Rhodes P. Estimated HIV prevalence in the United States at the end of 2003. National HIV Prevention Conference; June 2005; Atlanta. Abstract T1-B1101
http://www.aegis.com/conferences/NHIVPC/2005/T1-B1101.html

UN AIDS epidemic update. December 2006.
www.unaids.org

CDC. Guidelines for National Human Immunodeficiency Virus Case Surveillance, Including Monitoring for Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. MMWR 1999; 48(RR-13):1-28. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4813a1.htm

Epidemiology of HIV/AIDS--United States, 1981-2005. MMWR Morb Mortal Wkly Rep 2006; 55:589.
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5521a2.htm

Daar, ES, Little, S, Pitt, J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med 2001; 134:25

Pilcher, CD, Fiscus, SA, Nguyen, TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005; 352:1873

Hammer, SM, Saag, MS, Schechter, M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827
http://jama.ama-assn.org/cgi/content/full/296/7/827

Kassutto, S, Johnston, MN, Rosenberg, ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40:868
http://www.journals.uchicago.edu/doi/pdf/10.1086/428127

Kassutto, S, Maghsoudi, K, Johnston, MN, et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 2006; 42:1024
http://www.journals.uchicago.edu/doi/full/10.1086/500410

Hecht, FM, Wang, L, Collier, A, et al. A Multicenter Observational Study of the Potential Benefits of Initiating Combination Antiretroviral Therapy during Acute HIV Infection. J Infect Dis 2006; 194:725
http://www.journals.uchicago.edu/doi/full/10.1086/506616

Wood, E, Hogg, RS, Yip, B, et al. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts >= 200 cells/[mu]l. AIDS 2006; 20:1117.
http://www.aidsonline.com/pt/re/aids/abstract.00002030-200605120-00004.htm

Walensky, RP, Paltiel, AD, Losina, E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11
http://www.journals.uchicago.edu/doi/pdf/10.1086/505147

Hogg, RS, Yip, B, Chan, KJ, Wood, E. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568
http://jama.ama-assn.org/cgi/content/full/286/20/2568

Shafer, RW, Smeaton, LM, Robbins, GK, et al. Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. N Engl J Med 2003; 349:2304
https://content.nejm.org/cgi/content/abstract/349/24/2304

Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet 1996; 348:283

MacArthur, RD, Novak, RM, Peng, G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368:2125

Gallant, JE, DeJesus, E, Arribas, JR, et al. Tenofovir DF, emtricitabine, and efavirenz versus zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251
http://content.nejm.org/cgi/content/abstract/354/3/251

Grinsztejn, B, Nguyen, BY, Katlama, C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261

Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov/guidelines

Shet, A, Berry, L, Mohri, H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006; 41:439
http://www.jaids.org/pt/re/jaids/fulltext.00126334-200604010-00006.htm

Weinstock, HS, Zaidi, I, Heneine, W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174.
http://www.journals.uchicago.edu/doi/pdf/10.1086/420789

Bacheler, L, Jeffrey, S, Hanna, G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001; 75:4999
http://jvi.asm.org/cgi/content/full/75/11/4999

Gottlieb, GS, Sow, PS, Hawes, SE, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905
http://www.journals.uchicago.edu/doi/full/10.1086/339295

Nettles, RE, Kieffer, TL, Kwon, P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817
http://jama.ama-assn.org/cgi/content/full/293/7/817

Bangsberg, DR, Moss, AR, Deeks, SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004; 53:696
http://jac.oxfordjournals.org/cgi/content/full/53/5/696

Gross, R, Bilker, WB, Friedman, HM, Strom, BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001; 15:2109
http://www.aidsonline.com/pt/re/aids/fulltext.00002030-200111090-00006.htm

Stone VE. Optimizing the care of minority patients with HIV/AIDS. Clin Infect Dis 2004; 38:400-404
http://www.journals.uchicago.edu/doi/pdf/10.1086/380969